国家医保局公布一起医药咨询服务企业涉商业贿赂案

Core Viewpoint - The article discusses the investigation and administrative penalties imposed on Shanghai Haiyilai Enterprise Consulting Management Partnership for engaging in commercial bribery related to the marketing of a pharmaceutical product, specifically "Dahansuan Sodium Injection" [1][3]. Group 1: Investigation Details - In April 2025, the Shanghai Putuo District Market Supervision Administration discovered that the company was involved in commercial bribery during its market service activities in Shanghai [1]. - The company signed a one-year information service agreement with Shanghai Hongjian Pharmaceutical Co., Ltd. in January 2023 to promote the sales of "Dahansuan Sodium Injection" [2]. - The company promised to maintain and increase the total sales of the product in Shanghai and offered benefits to doctors to encourage them to prescribe the drug [2]. Group 2: Financial Transactions - Between January and December 2023, the sales promotion director made four payments totaling 35,046 yuan as bribes to a doctor in exchange for prescriptions of the drug, resulting in 18,275 units being prescribed [2]. - The total revenue from market promotion and information services for the product in 2023 amounted to 868,677 yuan [2]. Group 3: Legal and Regulatory Implications - The investigation was supported by various documents, including inquiry records, service agreements, and payment records, leading to the conclusion that the company violated the Anti-Unfair Competition Law of the People's Republic of China [3]. - The company was fined 300,000 yuan for its actions, which were deemed as commercial bribery aimed at increasing product sales [3]. Group 4: Industry Impact - The article highlights that pharmaceutical commercial bribery undermines fair competition and increases the burden on healthcare, shifting sales from clinical value to improper competition driven by high rebates [4]. - The National Healthcare Security Administration has implemented a credit evaluation system to address issues of bribery and misconduct in pharmaceutical sales, aiming to ensure fair competition and protect the rights of patients and compliant businesses [4].